A compound that activates glucagon receptors, increasing hepatic fat oxidation and overall energy expenditure through metabolic stimulation
In doing so the molecule is constantly docking and undocking and lengthening the drugs action
Critics of the Bridge program say the 18-month window may not be enough to evaluate its effectiveness, as doctors and patients need time to adjust dosages to minimize side effects
According to the World Health Organization (WHO), GLP-1 therapies short for glucagon-like peptide-1 receptor agonists work by mimicking a natural hormone that: Regulates appetite Slows stomach emptying Improves blood sugar control The WHO says GLP-1s were originally developed to treat type 2 diabetes
Weve known that GLP-1 drugs suppress feeding behaviour driven by energy demand, said co-corresponding author Ali Guler, a Professor of Biology at the University of Virginia
This prescription drug is part of a class of medicines called sodium-glucose co-transporter 2 (SGLT2) inhibitors